Gian CAMENISCH (Novartis) SITE

  • Drug Metab Dispos. 2020;48:873-885. Absorption, distribution, metabolism, and xxcretion of Capmatinib (INC280) in healthy male volunteers and in vitro Aldehyde Oxidase phenotyping of the major metabolite. Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, Jaap van Lier J, Borell H, Meissner A, Camenisch G, Zhao S. PubMed
  • Pharmacol Res Perspect. 2020;8:e00599. An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data. James AD, Schiller H, Marvalin C, Jin Y, Borell H, Roffel AF, Glaenzel U, Ji Y, Camenisch G. PubMed
  • Pulm Pharmacol Ther. 2019;57:101809. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, Elbast W, Schiller H, End P, Camenisch G, Weiss M. PubMed
  • Eur J Pharm Sci. 2019;132:132-141. Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical models. Riede J, Umehara KI, Schweigler P, Huth F, Schiller H, Camenisch G, Poller B. PubMed
  • Drug Metab Dispos. 2018;46:1670-1683. Models and approaches describing the metabolism, transport, and toxicity of drugs administered by the ocular route. Dumouchel JL, Chemuturi N, Milton MN, Camenisch G, Chastain J, Walles M, Sasseville V, Gunduz M, Iyer GR, Argikar UA. PubMed
  • Drug Metab Dispos. 2018;46:1001-1013. Metabolism and disposition of Siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A. PubMed
  • Bioanalysis. 2018;10:321-339. Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm. Lozac'h F, Fahrni S, Maria D, Welte C, Bourquin J, Synal HA, Pearson D, Walles M, Camenisch G. PubMed
  • Eur J Clin Pharmacol. 2018;74:455-464. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G. PubMed
  • Drug Metab Dispos. 2017;45:900-907. Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. James AD, Marvalin C, Luneau A, Meissner A, Camenisch G. PubMed
  • Drug Metab Dispos. 2017;45:817-825. Absorption, distribution, metabolism, and excretion of the oral Prostaglandin D2 receptor 2 antagonist Fevipiprant (QAW039) in healthy volunteers and in vitro. Pearson D, Weiss HM, Jin Y, Jaap van Lier J, Erpenbeck VJ, Glaenzel U, End P, Woessner R, Eggimann F, Camenisch G. PubMed
  • J Pharm Sci. 2017 Sep;106:2805-2814. Current in vitro methods to determine hepatic Kpuu: a comparison of their usefulness and limitations. Riede J, Camenisch G, Huwyler J, Poller B. PubMed
  • Drug Metab Dispos. 2017;45:523-531. Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations. Riede J, Poller B, Huwyler J, Camenisch G. PubMed
  • Pharm Res. 2016;33:2583-93. Drug Disposition Classification Systems in Discovery and Development: A comparative review of the BDDCS, ECCS and ECCCS concepts. Camenisch GP. PubMed
  • Eur J Pharm Sci. 2016;86:96-102. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. Riede J, Poller B, Umehara K, Huwyler J, Camenisch G. PubMed
  • Xenobiotica. 2016;46:862-7. Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors. Umehara K, Zollinger M, Kigondu E, Witschi M, Juif C, Huth F, Schiller H, Chibale K, Camenisch G. PubMed
  • Drug Metab Dispos. 2015;43:126-39. Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation. Manevski N, Swart P, Balavenkatraman KK, Bertschi B, Camenisch G, Kretz O, Schiller H, Walles M, Ling B, Wettstein R, Schaefer DJ, Itin P, Ashton-Chess J, Pognan F, Wolf A, Litherland K. PubMed
  • Drug Metab Dispos. 2014;42:1514-21. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Kunze A, Huwyler J, Camenisch G, Poller B. PubMed
  • J Pharm Sci. 2014;103:994-1001. In vitro-in vivo extrapolation method to predict human renal clearance of drugs. Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G. PubMed
  • Biochem Pharmacol. 2012;84:1096-102. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Kunze A, Huwyler J, Camenisch G, Gutmann H. PubMed
  • Biopharm Drug Dispos. 2012;33:179-94. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Camenisch G, Umehara K. PubMed
  • Pharm Res. 2012;29:603-17. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Umehara K, Camenisch G. PubMed
  • Biopharm Drug Dispos. 2002;23:251-62. The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats--in vitro and in vivo pharmacokinetic studies. Wiegand H, Wirz B, Schweitzer A, Camenisch GP, Rodriguez Perez MI, Gross G, Woessner R, Voges R, Arvidsson PI, Frackenpohl J, Seebach D. PubMed
  • Bioorg Med Chem Lett. 2001;11:1549-52. Cell permeability as a parameter for lead generation in the protein tyrosine kinase inhibition field. Papageorgiou C, Camenisch G, Borer X. PubMed
  • J Drug Target. 1998;6:151-65. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. PubMed
  • Eur J Pharm Sci. 1998;6:325-29. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Camenisch G, Folkers G, van de Waterbeemd H. PubMed
  • Eur J Pharm Sci. 1998;6:317-24. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs lipophilicity and molecular weight. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. PubMed
  • Pharm Acta Helv. 1996;71:309-27. Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Camenisch G, Folkers G, van de Waterbeemd H. PubMed


Basel, Switzerland

Last update: October 2021